Marshall Wace
Overview
Marshall Wace is a leading provider of alternative investment solutions. We manage quantitative, systematic and fundamental strategies, specialising in long/short equity. Our strategies are implemented globally, leveraging proprietary systems and processes. Technology and data have been at the core of our business for more than two decades. In 2002, we launched MW TOPS, the world's first 'Alpha Capture' application. Today, we continue to foster an environment focused on innovation and the pursuit of excellence.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Arc Money | May 2026 | Presale Round | Co-investor |
| Synopsys | May 2026 | Presale | Co-investor |
| Ray Therapeutics | Apr 2026 | Series B | Co-investor |
| Third Arc Bio | Feb 2026 | Series A Extension | Co-investor |
| Parabilis Medicines | Jan 2026 | Series F | Co-investor |
Key People
Amit Rajpal
Managing Partner And Portfolio Manager
Alex Fotin
Partner, Head Of Quantamental Research
Harvey Kingdom
Early Careers Recruitment Partner (Wiser)
Seb Barker
Partner
Claire Musgrave
Partner Finance Director
Jon May
Partner, General Counsel And Head Of Compliance
Kasia Konopacki
Principal
Christopher Eberle
Portfolio Manager - Global Tech
Daniel Gish
Portfolio Manager
Derek Rosenthal
Portfolio Manager
Divya Balakrishnan
Portfolio Manager
FIA Wajahat Rizvi
Portfolio Manager
Filipe Correia da Silva
Portfolio Manager
Gaurav Grover
Portfolio Manager
Hiroki Sugihara
Portfolio Manager
John Lu
Portfolio Manager
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
